SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending following Q3 earnings and a new AI partnership with Perplexity, with the community weighing in on a potential short squeeze. Bullish investors highlight the potential for AI monetization and a turnaround narrative, while bears question the stock's ability to hold gains. Discussions also focus on a stock buyback program and potential upgrades following earnings.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending as investors debate the impact of AI on its language learning platform. While some fear free AI translation apps could disrupt their business, others argue that language learning is irreplaceable and see long-term value, especially with growing revenue and user numbers. Community discussions also revolve around the recent stock drop following earnings, with some viewing it as a manipulation and buying opportunity.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending amid community discussions around its recent earnings report, with debates focusing on revenue growth, profitability, and valuation relative to competitors like Lemonade. While some investors express optimism about Root's long-term potential and strategic partnerships, others are concerned about slowing growth and potential market manipulation. The valuation gap between Root and competitors remains a key talking point.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors anticipate potential news, possibly a partnership or buyout, around the upcoming earnings call. Community discussions revolve around the possibility of a short squeeze, with some expressing frustration over the stock's performance and management's communication. Speculation about a potential deal with AstraZeneca is circulating, fueled by their aligned earnings call dates and a past real estate transaction.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as analysts weigh in following recent earnings and amid some volatility related to data privacy concerns and short-seller reports. The community is actively discussing price targets, potential SEC investigations, and the company's growth prospects in the mobile gaming and e-commerce sectors, with some anticipating a continued climb while others remain cautious.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending amid speculation around potential partnerships and recent insider buying, with community members closely watching resistance levels. SoftBank's earlier interest in a takeover is resurfacing in discussions. Despite sector tailwinds, the stock's YTD performance remains a key talking point.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty ($ELF) is trending due to a recent analyst downgrade from Piper Sandler, citing concerns about growth and profitability despite the Rhode brand acquisition, causing a sharp stock drop and sparking debate among investors about its valuation. Some see the dip as a buying opportunity, pointing to the brand's Gen Z appeal and potential tariff benefits, while others express skepticism about its growth prospects and caution against investing in makeup companies amid technological advancements.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as the community debates its potential amid accusations of competitor manipulation and a perceived battle between #base and #bnb chains. Discussions revolve around buybacks, locked developer tokens, and whether it is undervalued, with some calling for support from $COIN. Concerns about market manipulation and comparisons to similar tokens like $ASTER are prevalent.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending after announcing new AI chips aimed at data centers, causing a surge in stock price as investors weigh its potential against established players like Nvidia and AMD. The community is actively discussing the significance of this strategic shift, its competitive positioning, and the potential impact on Qualcomm's future revenue streams beyond the smartphone market. Some are skeptical of the company's ability to compete while others are bullish on its prospects in the AI space.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT) is trending as community members express strong conviction that the token is undervalued and poised for a future breakout. Many users are emphasizing the long-term potential of SWEAT, highlighting its association with a health-focused app that rewards users for physical activity. Discussions also mention the upcoming opportunities with staking and potential for burning unclaimed tokens, possibly driving increased interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of +21.43% and +5.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Prime Medicine stock soars amid gene editing sector momentum

Investing.com --  Prime Medicine  (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for  Verve Therapeutics  (NASDAQ:VERV) last month. 

Retail chatter for Prime Medicine spiked Monday following Citi's downgrade to 'Neutral' from 'Buy,' with the price target slashed to $1.50 from $10.&nbsp;According to Citi's research note, the shares were trading near cash, reflecting investor uncertainty over the company's path to value inflection.Citi said that Prime Medicine's cash reserves will sustain operations only until mid-2026 despite recent efforts to cut costs and restructure operations.However, management expects initial clinical data will become available for Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD) in 2027.Prime Medicine’s shares closed at $1.29 on Friday, up 4.88% or $0.06 for the day.The company said it would restructure by making its Chronic Granulomatous Disease (CGD) programs a lower priority while cutting its workforce by about 25% to concentrate on the liver disease franchise and externally funded programs.The firm maintains progress in its live studies that target two significant genetic liver conditions: Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD).It plans to file an investigational new drug (IND) application in the first half of 2026 and mid-2026, respectively. Initial clinical data for these programs are expected in 2027.Prime Medicine also maintains its cystic fibrosis program, which is supported by the Cystic Fibrosis Foundation, and collaborates with Bristol Myers Squibb to develop Prime Edited CAR-T products in hematology, immunology, and oncology.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user noted insider buying and a technical double bottom pattern, suggesting the stock could either become a complete write-off or achieve “legendary” success.<stembedurl>https://stocktwits.com/sogenerous/message/615704325</stembedurl>Meanwhile, another user highlighted the company's gene-editing technology and its long-term potential despite the lengthy clinical timelines.<stembedurl>https://stocktwits.com/Shesellsseashells/message/615286716</stembedurl>The stock has declined 57% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Citi Downgrade Sparks Retail Chatter On Prime Medicine Amid Cash Runway Uncertainty

The biotech firm announced a restructuring to focus on its liver disease programs while cutting costs and workforce amid ongoing development challenges.

Equity

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-strategic-restructuring-focus">announced</a> a strategic restructuring, including layoffs and the resignation of its CEO in a bid to reduce cash burn.Prime Medicine announced that Keith Gottesdiener will step down as CEO and a member of the company’s board of directors, effective immediately.Allan Reine, Prime Medicine’s Chief Financial Officer (CFO), will now succeed Gottesdiener.The company also announced the deprioritization of its programs aimed at the genetic disorder Chronic Granulomatous Disease (CGD), instead focusing its efforts on the development of programs for genetic liver diseases, Wilson’s Disease, and Alpha-1 Antitrypsin Deficiency (AATD).The company expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026 and its AATD program in mid-2026. Initial clinical data from both programs is expected the following year.For its CGD program, PM359, the company said it is exploring options for continued clinical development outside the firm.However, the company expressed confidence in the program and believes it has the potential to transform the treatment of the disorder.Prime Medicine also said it is reducing its organizational headcount by approximately 25%.The company believes the multiple initiatives will reduce anticipated cash needs by almost half through 2027.Prime Medicine expects that its cash, cash equivalents, and investments as of March 31, 2025, will be sufficient to fund its operations and capital expenditure requirements into the first half of 2026.On Stocktwits, retail sentiment around PRME rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_at_12_06_01_PM_png_ee21a5e357.webp" alt="PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits" width="628" height="65"><figcaption>PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/PRME">PRME stock</a> is down by about 57% this year and 83% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/protagenic-therapeutics-merges-with-phytanix-bio/ch0cuACRb8E">Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish

The company said Keith Gottesdiener will step down as the chief executive, while CFO Allan Reine will succeed him.

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK...

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Current Price	$4.40
Prev Close	$4.30
Open	$4.31
Dividend Yield	0.00%
50-Day Moving Average	$4.94
Beta	2.02
Avg. Volume	4.26M
PE Ratio	-2.75

52-Week High	$6.94
52-Week Low	$1.11
Market Capitalization	$784.06M
EPS (Annual)	-$1.65
Price to Book	9.72
Revenue Per Employee	$13,939.25
Enterprise Value/EBITDA	N/A

PRME
Prime Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRME News

PRMEPrime Medicine Inc